156 related articles for article (PubMed ID: 27028020)
1. Generalized keratosis pilaris-like eruptions in a chronic myelogenous leukemia patient treated with nilotinib.
Shimizu A; Hattori M; Takeuchi Y; Ishikawa O
J Dermatol; 2016 Sep; 43(9):1100-1. PubMed ID: 27028020
[No Abstract] [Full Text] [Related]
2. Chronic myeloid leukemia with a novel e8a1 BCR-ABL1 fusion: rapid molecular response with nilotinib.
Crampe M; Shakkak F; Kelly J; Hodgson A; Langabeer SE
Leuk Lymphoma; 2017 Sep; 58(9):1-6. PubMed ID: 28121203
[No Abstract] [Full Text] [Related]
3. Cross-intolerance to imatinib, dasatinib and nilotinib therapy in a patient with chronic myeloid leukaemia.
Novitzky-Basso I; Craddock C
Eur J Haematol; 2011 Jun; 86(6):548-9. PubMed ID: 21477076
[No Abstract] [Full Text] [Related]
4. Unusual widespread cutaneous eruption due to nilotinib therapy for chronic myeloid leukemia.
Brazzelli V; Grasso V; Elena C; Orlandi E; Borroni G
G Ital Dermatol Venereol; 2015 Oct; 150(5):623-5. PubMed ID: 25014583
[No Abstract] [Full Text] [Related]
5. Causes of resistance and treatment choices of second- and third-line treatment in chronic myelogenous leukemia patients.
Hochhaus A; Ernst T; Eigendorff E; La Rosée P
Ann Hematol; 2015 Apr; 94 Suppl 2():S133-40. PubMed ID: 25814079
[TBL] [Abstract][Full Text] [Related]
6. Massive bone marrow necrosis in a patient with chronic myelocytic leukemia following imatinib mesylate therapy.
Tamura T; Tasaka T; Fujimoto M; Matsuhashi Y; Fukumot T; Mano S; Kuwajima M; Nagai M
Haematologica; 2004 Sep; 89(9):ECR32. PubMed ID: 15377484
[No Abstract] [Full Text] [Related]
7. Cancer-drug discovery and cardiovascular surveillance.
Groarke JD; Cheng S; Moslehi J
N Engl J Med; 2013 Nov; 369(19):1779-81. PubMed ID: 24180496
[No Abstract] [Full Text] [Related]
8. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial.
Kantarjian HM; Hochhaus A; Saglio G; De Souza C; Flinn IW; Stenke L; Goh YT; Rosti G; Nakamae H; Gallagher NJ; Hoenekopp A; Blakesley RE; Larson RA; Hughes TP
Lancet Oncol; 2011 Sep; 12(9):841-51. PubMed ID: 21856226
[TBL] [Abstract][Full Text] [Related]
9. Keratosis pilaris-like eruption secondary to nilotinib in a child.
Oro-Ayude M; Feito M; Quintana-Castanedo L; Beato-Merino MJ; De Lucas R
Pediatr Dermatol; 2020 Sep; 37(5):968-969. PubMed ID: 32602176
[TBL] [Abstract][Full Text] [Related]
10. Nilotinib-induced liver injury: A case report.
Tan Y; Ye Y; Zhou X
Medicine (Baltimore); 2020 Sep; 99(36):e22061. PubMed ID: 32899072
[TBL] [Abstract][Full Text] [Related]
11. Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib.
Hughes TP; Saglio G; Kantarjian HM; Guilhot F; Niederwieser D; Rosti G; Nakaseko C; De Souza CA; Kalaycio ME; Meier S; Fan X; Menssen HD; Larson RA; Hochhaus A
Blood; 2014 Feb; 123(9):1353-60. PubMed ID: 24335106
[TBL] [Abstract][Full Text] [Related]
12. First-line therapy for CML: nilotinib comes of age.
Davies J
Lancet Oncol; 2011 Sep; 12(9):826-7. PubMed ID: 21856227
[No Abstract] [Full Text] [Related]
13. Risk of arterial and venous occlusive events in chronic myeloid leukemia patients treated with new generation BCR-ABL tyrosine kinase inhibitors: a systematic review and meta-analysis.
Haguet H; Douxfils J; Mullier F; Chatelain C; Graux C; Dogné JM
Expert Opin Drug Saf; 2017 Jan; 16(1):5-12. PubMed ID: 27852118
[TBL] [Abstract][Full Text] [Related]
14. Optimal Response in a Patient With CML Expressing
Manzella L; Tirrò E; Vitale SR; Puma A; Consoli ML; Tambè L; Pennisi MS; DI Gregorio S; Romano C; Tomarchio C; DI Raimondo F; Stagno F
In Vivo; 2020; 34(3):1481-1486. PubMed ID: 32354950
[TBL] [Abstract][Full Text] [Related]
15. Rapid onset of peripheral artery disease in a chronic myeloid leukemia patient without prior arterial disorder: direct relationship with nilotinib exposure and clinical outcome.
Mirault T; Rea D; Azarine A; Messas E
Eur J Haematol; 2015 Apr; 94(4):363-7. PubMed ID: 24797802
[TBL] [Abstract][Full Text] [Related]
16. Imatinib-related bone marrow aplasia after complete cytogenetic response in chronic myeloid leukemia.
Khan KA; Junaid A; Siddiqui NS; Mukhtar K; Siddiqui S
J Coll Physicians Surg Pak; 2008 Mar; 18(3):176-8. PubMed ID: 18460249
[TBL] [Abstract][Full Text] [Related]
17. Circulating unconventional T-cell subsets during treatment with BCR-ABL1 tyrosine kinase inhibitors for Philadelphia chromosome-positive leukemia.
Konuma T; Kohara C; Watanabe E; Mizukami M; Nagai E; Kato S; Takahashi S; Tojo A
Eur J Haematol; 2019 Dec; 103(6):623-625. PubMed ID: 31512295
[No Abstract] [Full Text] [Related]
18. Lichen planopilaris-like eruption during treatment with tyrosine kinase inhibitor nilotinib.
Leitão JR; Valente NY; Kakizaki P; Veronez IS; Pires MC
An Bras Dermatol; 2016; 91(5 suppl 1):45-47. PubMed ID: 28300891
[TBL] [Abstract][Full Text] [Related]
19. Nilontinib induced keratosis pilaris atrophicans.
Khetarpal S; Sood A; Billings SD
Dermatol Online J; 2016 Aug; 22(8):. PubMed ID: 27617940
[TBL] [Abstract][Full Text] [Related]
20. Drug evaluation: Nilotinib - a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of chronic myelocytic leukemia and beyond.
Jabbour E; Cortes J; Giles F; O'Brien S; Kantarijan H
IDrugs; 2007 Jul; 10(7):468-79. PubMed ID: 17642017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]